PHARMACEUTICAL COMPANY AstraZeneca will pay $1.1bn to resolve an ongoing transfer pricing dispute over its US business.
The UK-Swedish based firm will pay the $1.1bn net costs to US tax authorities to cover transfer pricing arrangements over a 13-year period from 2002 to the end of 2014, it announced today. It had already announced in February that it will pay £505m to settle a dispute with HM Revenue & Customs.
“AstraZeneca had provided in its accounts for the outcome of these issues, at the heart of which are complex transfer pricing considerations that have taken many years to resolve,” the group said.
It also said that the group’s effective tax rate for 2011 is expected to be approximately six percentage points lower than the previous guidance of 27%, at around 21%.
HMRC launches a consultation document that looks to strengthen government efforts against transfer mispricing
The England and Wales Cricket board has hit HMRC for six in its VAT battle with the government department
EC adopts rules on the reporting by multinational companies of tax-related information
The search engine's tax affairs have come under further scrutiny following a dawn raid on its Paris offices